Brian Thomas, Metagenomi CEO

Gene edit­ing start­up Metageno­mi fi­nal­ly sets IPO range, as pre­clin­i­cal biotech eyes $87M

Gene edit­ing com­pa­ny Metageno­mi has set a price range for its pro­posed ini­tial pub­lic of­fer­ing, mark­ing a key step for pre­clin­i­cal biotechs af­ter weeks of an­tic­i­pa­tion on whether the Cal­i­for­nia start­up would fol­low through with a list­ing.

Metageno­mi ex­pects net pro­ceeds of about $87 mil­lion if it prices at $16 per share, the mid­point of its pro­posed range dis­closed Mon­day morn­ing in an SEC fil­ing. The biotech will like­ly go pub­lic lat­er this week by sell­ing 6.25 mil­lion shares. There’s a chance its pro­ceeds could bal­loon if the com­pa­ny up­sizes be­fore land­ing on Nas­daq as “MGX,” as CG On­col­o­gy, Ar­riVent Bio­Phar­ma and Al­to Neu­ro­science did in the past two weeks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA